This review evaluates recent progress in nanozyme-based biosensors for detecting circulating tumour cells, nucleic acids, and protein biomarkers, with particular attention to how peroxidase-, oxidase-, and catalase-like reactions enhance signal generation across electrochemical, optical, and microfluidic platforms. The roles of iron oxide–gold composites, silica nanostructures, quantum dots, and hybrid nanomaterials in improving analytical performance, enabling multiplexed detection, and facilitating assay miniaturization are critically assessed. Advances such as amplification-free detection approaches, smartphone-compatible point-of-care systems, and AI-assisted data analysis are discussed in relation to their translational potential. Key barriers, including regulatory requirements, reproducibility concerns, and manufacturing scalability, are also evaluated. By integrating mechanistic understanding with practical considerations for clinical deployment, this review outlines how next-generation nanozyme-based biosensors may strengthen early cancer detection, real-time monitoring, and precision oncology.
Akpe et al. (Tue,) studied this question.